Table 2.

CLL and HCMBL by TP53 mutation status

CLL	No TP53 mutation (n = 748)		VAF ≤10% (n = 37)		VAF >10% (n = 64)		Overall (n = 849)
Female, n, %	223	29.8	13	5.0	22	8.5	258	30.4
Male, n, %	525	70.2	24	4.1	42	7.1	591	69.6
Median age (IQR), y	61 (46-76)		65 (55-75)		66.5 (50-83)		61 (46-76)
Rai stage 0, n, %	405	55.4	20	55.6	31	49.2	456	54.9
Rai stage 1-4, n, %	326	44.6	16	44.4	32	50.8	374	45.1
Median β2M (IQR), mg/L	2.4 (1.1-3.7)		2.9 (1.1-4.8)		2.9 (1.1-4.6)		2.4 (1.1-3.8)
IGHV unmutated, n, %	343	49.0	24	68.6	39	65.0	406	51.1
IGHV mutated, n, %	357	51.0	11	31.4	21	35.0	389	48.9
FISH del(11q), n, %	84	11.2	2	5.4	3	4.7	89	10.5
FISH del(13q), n, %	370	49.5	19	51.4	42	65.6	431	50.8
FISH tri(12), n, %	103	13.8	4	10.8	3	4.7	110	13.0
FISH/CNV del(17p), n, %	10	1.3	7	18.9	41	64.1	58	6.8
Median follow-up, y	6.21		5.49		4.54		5.95

HCMBL	No TP53 mutation (n = 348)		VAF ≤10% (n = 16)		VAF >10% (n = 17)		Overall (n = 381)
Female, n, %	130	37.4	1	6.3	7	41.2	138	36.2
Male, n, %	218	62.6	15	93.8	10	58.8	243	63.8
Median age (IQR), y	67 (53-81)		74 (63-85)		70 (57-83)		67 (52-82)
Median β2M (IQR), mg/L	2.1 (1.4-2.8)		2.2 (1.5-2.9)		2.2 (0.6-3.9)		2.1 (1.4-2.8)
IGHV unmutated, n, %	66	25.0	1	8.3	4	30.8	71	24.6
IGHV mutated, n, %	198	75.0	11	91.7	9	69.2	218	75.4
FISH del(11q), n, %	13	3.7	1	6.3	1	5.9	15	3.9
FISH del(13q), n, %	145	41.7	8	50.0	7	41.2	160	42.0
FISH tri(12), n, %	47	13.5	1	6.3	0	0.0	48	12.6
FISH/CNV del(17p), n, %	3	0.9	1	6.3	7	41.2	11	2.9
Median follow-up, y	7.18		7.65		6.2		7.27